- Home
- INKT vs GDTC Comparison
INKT vs GDTC Comparison
Compare INKT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- GDTC
- Stock Information
- Founded
- INKT 2017
- GDTC 2018
- Country
- INKT United States
- GDTC Singapore
- Employees
- INKT N/A
- GDTC N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- GDTC Health Care
- Exchange
- INKT Nasdaq
- GDTC Nasdaq
- Market Cap
- INKT 69.2M
- GDTC 21.5M
- IPO Year
- INKT 2021
- GDTC 2023
- Fundamental
- Price
- INKT $14.24
- GDTC $1.88
- Analyst Decision
- INKT Buy
- GDTC Buy
- Analyst Count
- INKT 3
- GDTC 1
- Target Price
- INKT $37.50
- GDTC $5.00
- AVG Volume (30 Days)
- INKT 45.1K
- GDTC 14.8K
- Earning Date
- INKT 11-13-2025
- GDTC 01-01-0001
- Dividend Yield
- INKT N/A
- GDTC N/A
- EPS Growth
- INKT N/A
- GDTC N/A
- EPS
- INKT N/A
- GDTC N/A
- Revenue
- INKT N/A
- GDTC $368,838.00
- Revenue This Year
- INKT N/A
- GDTC $5.37
- Revenue Next Year
- INKT N/A
- GDTC N/A
- P/E Ratio
- INKT N/A
- GDTC N/A
- Revenue Growth
- INKT N/A
- GDTC N/A
- 52 Week Low
- INKT $4.56
- GDTC $1.20
- 52 Week High
- INKT $76.00
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- INKT 47.11
- GDTC 46.04
- Support Level
- INKT $13.11
- GDTC $1.82
- Resistance Level
- INKT $16.20
- GDTC $2.28
- Average True Range (ATR)
- INKT 1.13
- GDTC 0.12
- MACD
- INKT -0.01
- GDTC 0.00
- Stochastic Oscillator
- INKT 35.38
- GDTC 13.04
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.